Abstract
Conformationally compromised oncogenic mutants of the tumor suppressor protein p53 can, in principle, be rescued by small molecules that bind the native, but not the denatured state. We describe a strategy for the rational search for such molecules. A nine-residue peptide, CDB3, which was derived from a p53 binding protein, binds to p53 core domain and stabilizes it in vitro. NMR studies showed that CDB3 bound to p53 at the edge of the DNA binding site, partly overlapping it. The fluorescein-labeled peptide, FL-CDB3, binds wild-type p53 core domain with a dissociation constant of 0.5 microM, and raises the apparent melting temperatures of wild-type and a representative oncogenic mutant, R249S core domain. gadd45 DNA competes with CDB3 and displaces it from its binding site. But this competition does not preclude CDB3 from being a lead compound. CDB3 may act as a "chaperone" that maintains existing or newly synthesized destabilized p53 mutants in a native conformation and then allows transfer to specific DNA, which binds more tightly. Indeed, CDB3 restored specific DNA binding activity to a highly destabilized mutant I195T to close to that of wild-type level.
MeSH Terms
Amino Acid Sequence
Base Sequence
Binding Sites/genetics
Binding, Competitive
DNA/genetics,metabolism
Drug Stability
Humans
In Vitro Techniques
Models, Molecular
Molecular Chaperones/metabolism
Molecular Sequence Data
Mutation
Oligopeptides/metabolism
Peptide Fragments/chemistry,genetics,metabolism
Protein Binding
Protein Folding
Protein Structure, Tertiary
Tumor Suppressor Protein p53/chemistry,genetics,metabolism
Chemicals
Molecular Chaperones
Oligopeptides
Peptide Fragments
Tumor Suppressor Protein p53
DNA
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Friedler Assaf
Cambridge University Chemical Laboratory and Cambridge Centre for Protein Engineering, Medical Research Council Centre, Hills Road, Cambridge CB2 2QH, United Kingdom.
Hansson Lars O
Veprintsev Dmitry B
Freund Stefan M V
Rippin Thomas M
Nikolova Penka V
Proctor Mark R
Rüdiger Stefan
Fersht Alan R
References (23)
23 references, click to expand
-
Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.
Oncogene. 2000 Mar 2;19(10):1245-56
PMID: 10713666
-
Pharmacological rescue of mutant p53 conformation and function.
Science. 1999 Dec 24;286(5449):2507-10
PMID: 10617466
-
Strategies for manipulating the p53 pathway in the treatment of human cancer.
Biochem J. 2000 Nov 15;352 Pt 1:1-17
PMID: 11062053
-
ASPP proteins specifically stimulate the apoptotic function of p53.
Mol Cell. 2001 Oct;8(4):781-94
PMID: 11684014
-
Rescuing the function of mutant p53.
Nat Rev Cancer. 2001 Oct;1(1):68-76
PMID: 11900253
-
Two cellular proteins that bind to wild-type but not mutant p53.
Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6098-102
PMID: 8016121
-
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.
Science. 1994 Jul 15;265(5170):346-55
PMID: 8023157
-
Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases.
J Biol Chem. 1995 Mar 10;270(10):5405-11
PMID: 7534296
-
The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity.
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5729-33
PMID: 7777576
-
Small peptides activate the latent sequence-specific DNA binding function of p53.
Cell. 1995 Oct 20;83(2):237-45
PMID: 7585941
-
Competition BIAcore for measuring true affinities: large differences from values determined from binding kinetics.
Anal Biochem. 1996 Feb 15;234(2):155-65
PMID: 8714593
-
Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2.
Science. 1996 Nov 8;274(5289):1001-5
PMID: 8875926
-
Restoration of the transcription activation function to mutant p53 in human cancer cells.
Oncogene. 1996 Dec 5;13(11):2477-82
PMID: 8957091
-
Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain.
Nat Med. 1997 Jun;3(6):632-8
PMID: 9176489
-
Thermodynamic stability of wild-type and mutant p53 core domain.
Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14338-42
PMID: 9405613
-
SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling.
Electrophoresis. 1997 Dec;18(15):2714-23
PMID: 9504803
-
Identification of an additional negative regulatory region for p53 sequence-specific DNA binding.
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6079-84
PMID: 9600920
-
Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2.
J Biol Chem. 1998 Oct 2;273(40):26061-8
PMID: 9748285
-
Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain.
Mol Cell Biol. 1999 May;19(5):3395-402
PMID: 10207063
-
Hot-spot mutants of p53 core domain evince characteristic local structural changes.
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8438-42
PMID: 10411893
-
p53 and human cancer: the first ten thousand mutations.
Adv Cancer Res. 2000;77:81-137
PMID: 10549356
-
Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells.
J Biol Chem. 1999 Dec 3;274(49):34924-31
PMID: 10574967
-
Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53.
Mol Cell Biol. 2000 Nov;20(21):8018-25
PMID: 11027272